Interviews

A new platform comprehensively profiles CAR T-cells during manufacturing, revealing phenotypic shifts. This allows for shorter timelines, better outcomes, and personalized therapies.

Ravindra Uppaluri, MD, PhD, discusses findings from the KEYNOTE-689 trial in adult patients with resectable, locally advanced head and neck squamous cell carcinoma.

Ravindra Uppaluri, MD, PhD, discusses the background regarding locally advanced head and neck cancer and what the trial design of KEYNOTE-689 entailed.

Taletrectinib emerges as a groundbreaking treatment for ROS1-mutant NSCLC, offering hope with its CNS activity and lower neurological side effects.

Paolo Ghia, MD, PhD, discusses results from the final analysis of the CAPTIVATE study in CLL/SLL.

Travel barriers and lack of local sites hinder clinical trial enrollment for underserved patients, and decentralizing trials is key to improving access, according to Mariam Eskander, MD, MPH.

Living in food deserts, clinical trial deserts, and areas with high transportation vulnerability significantly lowers breast cancer clinical trial participation.

Paolo Ghia, MD, PhD, discusses the final analysis of the CAPTIVATE study.

Hyung Kim, MD, discussed the PROBE trial, a trial in progress, for patients with advanced kidney cancer.

Seven-year follow-up data on over 1400 patients show radium-223's long-term safety, with a low 2% secondary malignancy rate, reflecting real-world use.

Jill Feldman discusses the background of the phase 2 COCOON trial in advanced non–small cell lung cancer with EGFR mutations.

Brian P. Mulherin, MD, shares his key takeaways from the 2025 ASCO Annual Meeting, highlighting significant advancements in SCLC and the challenge of information overload at large conferences.

Sara Char, MD, discusses how inflammatory diets impact colon cancer survival rates.

Zeynep Eroglu, MD, discusses the use of a triplet regimen vs standard doublet therapy for the treatment of brain metastases in patients with melanoma.

A groundbreaking trial explores pembrolizumab's role in enhancing treatment outcomes for advanced head and neck cancer, promising significant advancements in patient care.

Discover the groundbreaking AMPLITUDE trial results, showcasing niraparib's effectiveness in treating metastatic prostate cancer with minimal safety concerns.

Yelena Y. Janjigian, MD, discusses how findings from the MATTERHORN trial presented at ASCO 2025 build upon previous research.

Jamie Jacobs, PhD, discusses a study assessing the BMT-CARE App, a self-guided digital intervention for caregivers of patients undergoing stem cell transplant.

A recent trial reveals that durvalumab enhances event-free survival in patients with resectable gastric and gastroesophageal junction adenocarcinoma.

Vepdegestrant shows significant progression-free survival benefits over fulvestrant in advanced breast cancer, highlighting its potential as a targeted treatment option.

Stephen V. Liu, MD, discusses the phase 3 IMforte study of lurbinectedin and atezolizumab in extended-stage small cell lung cancer.

Sophia Kamran, MD, discussed the updated AUA guidelines on salvage therapy for patients with prostate cancer and their implications.

Cervical cancer prevention advances with new immunotherapy findings, addressing disparities and improving outcomes for underserved women globally.

Alfred L. Garfall, MD, provided a deep dive into the phase 2 BMT CTN 1902 trial of ide-cel in multiple myeloma after transplant.

Massimo Cristofanilli, MD, discusses the role of cell-free DNA in breast cancer.

Zipalertinib shows promising efficacy and safety for advanced NSCLC with EGFR exon 20 mutations, offering a much-needed oral treatment option.

Theresa Medina, MD, discusses treatment with lifileucel in patients with advanced melanoma and the background of the C-144-01 study.